Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care
Elyse L. Tung A B E , Annalisa Thomas A B , Allyson Eichner A B and Peter Shalit C D
+ Author Affiliations
- Author Affiliations
A Kelley-Ross Pharmacy Group, 904 7th Avenue, Suite 103, Seattle, WA 98104, USA.
B University of Washington School of Pharmacy, Box 357630, Seattle, WA 98195, USA.
C Peter Shalit MD and Associates, 901 Boren Avenue, Suite 850, Seattle, WA 98104, USA.
D University of Washington School of Medicine, Box 356523, Seattle, WA 98195, USA.
E Corresponding author. Email: etung@kelley-ross.com
Sexual Health 15(6) 556-561 https://doi.org/10.1071/SH18084
Submitted: 24 April 2018 Accepted: 30 August 2018 Published: 7 November 2018
Abstract
Background: National guidelines for the provision of HIV pre-exposure prophylaxis (PrEP) to reduce a person’s risk of acquiring HIV were made available in 2014. We created a pharmacist-managed HIV PrEP clinic in a community pharmacy setting at Kelley-Ross Pharmacy in Seattle, WA, USA. Methods: The clinic operates under a collaborative drug therapy agreement based on these guidelines. This allows pharmacists to initiate and manage tenofovir disoproxil fumarate/emtricitabine under the supervision of a physician medical director. Results: Between March 2015 and February 2018, 714 patients were evaluated and 695 (97.3%) initiated PrEP. Five hundred and thirteen (74%) patients began medication the same day as their initial appointment. Of the prescriptions filled in our pharmacy, 90% of patients had a mean proportion of days covered (PDC) greater than 80%, and 98% had a zero-dollar patient responsibility per month, including uninsured individuals. 19% of patients were lost to follow up, with an effective drop-out rate of 25%. Two hundred and seven diagnoses of sexually transmissible infections were made. There were no HIV seroconversions in the service. Conclusion: The pharmacist-managed PrEP clinic proved to be a successful alternative model of PrEP care, with high initiation rates and low drop-out and lost-to-follow-up rates. This may benefit individuals who do not access PrEP in traditional health care settings or where PrEP access is scarce. Financial sustainability of the model was dependent on the ability of pharmacists in the clinic to bill insurance plans for their services in accordance with Washington State legislative changes requiring commercial insurances to recognise pharmacists as providers.
Additional keywords: PrEP adherence, PrEP clinic, pharmacist-managed PrEP.
References
[1] Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for prevention of HIV infection in the United States – 2017 update: a clinical practice guideline. 2018. Available online at: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf [verified 23 October 2018].[2] Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker L-G, Mayer KH, Kallás EG, Rivet Amico K, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng J-H, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV, for the iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363 2587–99.
| Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.Crossref | GoogleScholarGoogle Scholar |
[3] Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kittimunkong S, Chuachoowong R, Gvetadze RJ, McNicholl JM, Paxton LA, Curlin ME, Hendrix CW, Vanichseni S, Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381 2083–90.
| Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.Crossref | GoogleScholarGoogle Scholar |
[4] Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C, for the Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367 399–410.
| Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.Crossref | GoogleScholarGoogle Scholar |
[5] Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, Mayer KH, Collins BM, Pathak SR, O’Hara B, Ackers ML, Rose CE, Grant RM, Paxton LA, Buchbinder SP. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr 2013; 64 79–86.
| Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.Crossref | GoogleScholarGoogle Scholar |
[6] Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT, for the TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367 423–34.
| Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.Crossref | GoogleScholarGoogle Scholar |
[7] Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak’Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D, for the FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367 411–22.
| Preexposure prophylaxis for HIV infection among African women.Crossref | GoogleScholarGoogle Scholar |
[8] Smith DK, Van Handel M, Grey JA. By race/ethnicity, blacks have highest number needing PrEP in the United States, 2015. Conference on retroviruses and Opportunistic Infections; 4–7 March 2018; Boston, MA, USA. Abstract 86. Atlanta, GA, USA: CDC; 2018.
[9] National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Newsroom. HIV prevention pill not reaching most Americans who could benefit – especially people of color. [press release] (6 March 2018). Atlanta, GA, USA: Centers for Disease Control and Prevention; 2018. Available online at: https://www.cdc.gov/nchhstp/newsroom/2018/croi-2018-PrEP-press-release.html [verified 17 March 2018].
[10] ModernMedicine Network. Drug Topic. NACDS 2010–2011 Chain Pharmacy Industry Profile Illustrates Pharmacy Value. UBM Medica, LLC; 2018. Available online at: http://drugtopics.modernmedicine.com/drug-topics/news/modernmedicine/modern-medicine-news/nacds- 2010-2011-chain-pharmacy-industry-profile?page=full [verified 31 October 2017].
[11] Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors. Arch Intern Med 2011; 171 1441–53.
| Impact of pharmacist care in the management of cardiovascular disease risk factors.Crossref | GoogleScholarGoogle Scholar |
[12] Manzoor BS, Cheng WH, Lee JC, Uppuluri EM, Nutescu EA. Quality of pharmacist-managed anticoagulation therapy in long-term ambulatory settings: a systematic review. Ann Pharmacother 2017; 51 1122–37.
| Quality of pharmacist-managed anticoagulation therapy in long-term ambulatory settings: a systematic review.Crossref | GoogleScholarGoogle Scholar |
[13] Amesty S, Crawford ND, Nandi V, Perez-Figueroa R, Rivera A, Sutton M, Weidle PJ, Willis L, Smith DK, Hernandez C, Harripersaud K, Lewis CF. Evaluation of pharmacy-based HIV testing in a high-risk New York City community. AIDS Patient Care STDS 2015; 29 437–44.
| Evaluation of pharmacy-based HIV testing in a high-risk New York City community.Crossref | GoogleScholarGoogle Scholar |
[14] Dugdale C, Zaller N, Bratberg J, Berk W, Flanigan T. Missed opportunities for HIV screening in pharmacies and retail clinics. J Manag Care Spec Pharm 2014; 20 339–45.
[15] Collins BC, Bronson HW, Martin EG. Assessing the efficacy and feasibility of a retail pharmacy-based HIV testing program. Conference on Retroviruses and Opportunistic Infections; 13–16 February 2017; Seattle, WA, USA. Abstract 962. Richmond, VA, USA: Virginia Department of Health; 2017.
[16] Centers for Disease Control and Prevention. Advancing team-based care through collaborative practice agreements: a resource and implementation guide for adding pharmacists to the care team. Atlanta, GA, USA: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2017. Available online at: https://www.cdc.gov/dhdsp/pubs/docs/CPA-Team-Based-Care.pdf [verified 12 February 2018].
[17] Patel R, Federman S, Tung E, Scales D. Pharmacy-based pre-exposure prophylaxis for the prevention of HIV: innovative service delivery models. Atlanta, GA, USA: National Coordinating Resource Center, Centers for Disease Control and Prevention; 2017.
[18] Bruno C, Saberi P. Pharmacists as providers of HIV pre-exposure prophylaxis. Int J Clin Pharm 2012; 34 803–6.
[19] Mayer KH, Chan PA, Patel RR, Flash CA, Krakower DS. Evolving models and ongoing challenges for HIV preexposure prophylaxis implementation in the United States. J Acquir Immune Defic Syndr 2018; 77 119–27.
[20] Workowski KA, Bolan GA, Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64 1–137.
[21] Engrossed Substitute Senate Bill 5557, 64th Legislature. 2015 Regular Session. Olympia, WA, USA: Washington State; 2015.
[22] Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, Anderson PL, Glidden D, Guanira J, Grant R. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr 2014; 66 530–7.
| Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection.Crossref | GoogleScholarGoogle Scholar |
[23] Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother 2009; 43 36–44.
| Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication.Crossref | GoogleScholarGoogle Scholar |
[24] Washington State Department of Health. Pre-exposure Prophylaxis Drug Assistance Program (PrEP DAP). Olympia, WA, USA: Washington State Department of Health; 2018. Available online at: https://www.doh.wa.gov/YouandYourFamily/IllnessandDisease/HIVAIDS/HIVPrevention/PrEPDAP [verified 16 March 2018].
[25] Dombrowski JC, Golden MR, Barbee LA, Khosropour CM. Patient disengagement from an HIV preexposure prophylaxis program in a sexually transmitted disease clinic. Sex Transm Dis 2018; 45 e62–4.
[26] Chan PA, Leandro M, Rupa P, Oldenburg CE, Beauchamps L, Perez-Brumer AG, Parker S, Mayer KH, Mimiaga MJ, Nunn A. Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Int AIDS Soc 2016; 19 20903
| Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities.Crossref | GoogleScholarGoogle Scholar |
[27] Bhatia R, Modali L, Lowther M, Glick N, Bell M, Rowan S, Keglovitz K, Schneider J. Outcomes of preexposure prophylaxis referrals from public STI clinics and implications for preexposure prophylaxis continuum. Sex Transm Dis 2018; 45 50–5.
[28] Hojilla JC, Vlahov D, Crouch PC, Dawson-Rose C, Freeborn K, Carrico A. HIV pre-exposure prophylaxis (PrEP) uptake and retention among men who have sex with men in a community-based sexual health clinic. AIDS Behav 2018; 22 1096–9.
| HIV pre-exposure prophylaxis (PrEP) uptake and retention among men who have sex with men in a community-based sexual health clinic.Crossref | GoogleScholarGoogle Scholar |
